SureTrader
Interactive Brokers Advertisement
Home > Boards > US Listed > Biotechs >

Aurinia Pharmaceuticals Inc (AUPH)

AUPH RSS Feed
Add AUPH Price Alert      Hide Sticky   Hide Intro
Moderator: Jesspro
Search This Board: 
Last Post: 10/17/2017 1:14:19 PM - Followers: 144 - Board type: Free - Posts Today: 0

Aurinia is a late-stage biopharmaceutical company providing novel products specifically engineered to treat a limited, targeted patient population suffering from serious disease states for which there is a high unmet medical need.

*Aurinia Pharmaceuticals Inc.
http://www.auriniapharma.com/
 

Pipeline

 

Pipeline

Pipeline

Candidate & Indication Development Stage
Preclinical Phase 1 Phase 2 Phase 3 Market
VOCLOSPORINLupus Nephritis (LN)
Preclinical Phase complete
Phase 1 Phase complete
Phase 2 Phase in progress
Phase 3 Phase not started
Market Phase not started

Aurinia is committed to working in areas of high unmet medical need and is poised to deliver the first approved therapy in the U.S. and Europe for the treatment of lupus nephritis, or LN.

The Voclosporin Advantage

Voclosporin, an investigational drug, is a novel and potentially best-in-class calcineurin inhibitor (“CNI”) with clinical data in over 2,000 patients across indications. Voclosporin is an immunosuppressant, with a synergistic and dual mechanism of action that has the potential to improve near- and long-term outcomes in lupus nephritis (LN) when added to standard of care mycophenolate mofetil (MMF). It has been granted “fast track status” by the U.S. Food & Drug Administration (FDA).

Voclosporin Could Transform the LN treatment Landscape

Voclosporin has the potential to become a best in class medication and the first approved treatment for LN in the U.S. and Europe, effectively altering the current treatment paradigm for the disease.

Advantages of Voclosporin Combined with Standard of Care (SoC)

Our clinical data suggests that adding voclosporin to the current SoC of MMF for the treatment of lupus nephritis (LN) will yield superior results to using the standard of care alone.

Additionally, voclosporin may prove to be an ideal therapy for lupus nephritis due to advantages such as:

  • Improved efficacy
    Increased safety
    Oral administration
    Improved average time to renal response or remission
    Improved duration of renal response
    Reduction in steroid burden
    Potential first line add-on to MMF
    Fewer toxic immunosuppressants required
Benefits of Voclosporin

Potential Benefits of Voclosporin

In clinical trials, Voclosporin has been shown to be especially effective in the presence of low dose steroids with rapid reduction of LN inflammatory markers and overall improved renal stability.

The list of potential product benefits includes:

LN Critical Need Voclosporin (based on AURA Results)
Control of Active Disease
Rapid Disease Control
Lower Steroid Burden
Impact on Extra-renal disease
Convenient Treatment Regimen

In previous studies, over 2000 patients have been treated with Voclosporin with no abnormal or unexpected SAE’s

Well Characterized Safety Profile

Efficacy of calcineurin inhibition has already been established. Voclosporin has a well-characterized safety profile (over 2,000 patient exposures across multiple years) across indications.

No new safety signals were observed with the use of Voclosporin in LN patients; Voclosporin was well-tolerated and renal function remained stable in clinical studies. The overall safety profile is consistent with other immunosuppressive drugs.

 

SureTrader
Interactive Brokers Advertisement
AUPH
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
PostSubject
#4884  Sticky Note AUPH: Now that Ph3 for LN is underway Lunacy aka John Galt 07/19/17 06:05:27 PM
#5767   Interesting news item regarding AstraZeneca/Roche, 3 others. ThePromise247 10/17/17 01:14:19 PM
#5766   In the American usage of the English language biotech_researcher 10/17/17 11:24:24 AM
#5765   the adjective original is not gradable, therefore the LadiesMan 10/17/17 11:07:09 AM
#5764   "moosedogger, must you copy everything I post?:" moosedogger 10/17/17 09:57:39 AM
#5763   moosedogger, must you copy everything I post?: Biotech biotech_researcher 10/17/17 09:39:19 AM
#5762   "....when I buy a stock and it goes moosedogger 10/17/17 09:33:54 AM
#5761   ASTRAZENECA could be a candidate to buy AUPH. Jesspro 10/16/17 07:43:36 PM
#5760   https://seekingalpha.com/article/4113752-aurinia-pharmaceuticals-10-biotech-stoc Inoviorulez 10/16/17 05:16:53 PM
#5759   I think the tutes need to short auph tiv111 10/16/17 03:07:54 PM
#5758   Just got another notification from Charles Schwab that Maciste 10/16/17 03:05:52 PM
#5757   It’s a big win for all of us Jesspro 10/16/17 01:42:10 PM
#5756   Fair enough; I figured Girlfriend seems to Maciste 10/16/17 01:37:44 PM
#5755   I am...LOL. Actually it is a BIG girlfriend 10/16/17 01:36:29 PM
#5754   Maciste, I will monitor your deal with GF. Jesspro 10/16/17 01:34:46 PM
#5753   I figured it was something said...thanks girlfriend 10/16/17 12:54:20 PM
#5752   Trump made mention of prescription drug prices being SvsB 10/16/17 12:50:12 PM
#5751   Deal. Maciste 10/16/17 12:49:58 PM
#5750   "Itchy fingers are for amatuers. That's why you SvsB 10/16/17 12:48:55 PM
#5749   IF either AUPH, AVXL, or ADXS doubles before girlfriend 10/16/17 12:48:38 PM
#5748   Girlfriend I would like to buy you a Latte. Maciste 10/16/17 12:46:09 PM
#5747   What specifically did I say that was dumb? SvsB 10/16/17 12:33:30 PM
#5746   I noticed that quite a few bios have girlfriend 10/16/17 12:31:34 PM
#5745   I DO NOT know more about this company biotech_researcher 10/16/17 12:25:50 PM
#5744   OK BR since you know more about this Maciste 10/16/17 12:14:57 PM
#5743   Dumb statements are relative to someone’s ears. What Jesspro 10/16/17 11:13:58 AM
#5742   Only when they make dumb statements... biotech_researcher 10/16/17 10:05:15 AM
#5741   Really good new for AUPH. Buckle Up as biotech_researcher 10/16/17 10:04:07 AM
#5740   Always dismissing of others aren't you? Indeed. Maciste 10/16/17 09:05:48 AM
#5739   SvsB, I don’t think you understand this stock. biotech_researcher 10/16/17 07:34:32 AM
#5738   Very Excited about this Friday's Voclosporin Indications Announcement! ThePromise247 10/16/17 05:57:59 AM
#5737   tweetindeed cervelo 10/15/17 09:03:47 PM
#5736   Itchy fingers are for amatuers. That's why you SvsB 10/15/17 07:39:08 PM
#5735   Aurinia to Host R&D Day and Webcast on biotech_researcher 10/15/17 07:15:30 PM
#5734   Getting itchy fingers and selling when your investment Lunacy aka John Galt 10/15/17 06:32:35 PM
#5733   Sorry Jess, didn’t intend to be a negative biotech_researcher 10/15/17 06:18:43 PM
#5732   Planting the seed of doubts again, huh? That Jesspro 10/15/17 05:50:56 PM
#5731   SvsB, your convictions have nothing to do with biotech_researcher 10/15/17 04:51:15 PM
#5730   I have my own convictions on why I'm SvsB 10/15/17 03:50:49 PM
#5729   “Who really cares what they do?” As a shareholder, biotech_researcher 10/15/17 02:31:54 PM
#5728   Who realy cares what they do? The fundementals SvsB 10/15/17 02:09:39 PM
#5727   Indeed!! Maciste 10/15/17 01:19:49 PM
#5726   It's easy to draw a down trend line Pencow 10/15/17 01:00:03 PM
#5725   Listen, I like you more the last two Jesspro 10/15/17 11:26:50 AM
#5724   Jess, we should make it to $11 pretty biotech_researcher 10/15/17 11:11:01 AM
#5723   So, do you think yours is increasing just Jesspro 10/15/17 11:04:31 AM
#5722   "... will have to see if these new moosedogger 10/15/17 10:59:22 AM
#5721   Moose, this still holds true. We will have biotech_researcher 10/15/17 10:23:23 AM
#5720   "....selling pressure now for folks wanting to cash moosedogger 10/15/17 10:13:19 AM
#5719   Jess, I believes it grows proportional to the biotech_researcher 10/15/17 09:57:38 AM
#5718   Guys, ever wonder how long Pinocchio’s nose is? Jesspro 10/15/17 08:12:54 AM
PostSubject